Zacks Investment Research downgraded shares of Galena Biopharma Inc. (GALE) from OUTPERFORM to NEUTRAL on March 18, 2014, with a target price of $3.25.
We are dropping coverage of Galena Biopharma to focus our resource elsewhere in the biotech sector. Our last rating is Neutral, with a $3.25 price target. Investors should no longer count on the accuracy of our estimates or financial projections.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on Galena Biopharma Inc. (GALE),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment